Evoke Pharma Price to Sales Ratio 2012-2024 | EVOK
Historical PS ratio values for Evoke Pharma (EVOK) over the last 10 years. The current P/S ratio for Evoke Pharma as of November 20, 2024 is .
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Evoke Pharma P/S Ratio Historical Data |
Date |
Stock Price |
TTM Sales per Share |
Price to Sales Ratio |
2024-11-20 |
4.56 |
|
0.38 |
2024-09-30 |
4.76 |
$12.08 |
0.39 |
2024-06-30 |
6.35 |
$15.78 |
0.40 |
2024-03-31 |
7.32 |
$17.97 |
0.41 |
2023-12-31 |
12.60 |
$18.58 |
0.68 |
2023-09-30 |
16.56 |
$15.61 |
1.06 |
2023-06-30 |
19.80 |
$12.99 |
1.52 |
2023-03-31 |
22.80 |
$10.69 |
2.13 |
2022-12-31 |
32.16 |
$9.62 |
3.34 |
2022-09-30 |
22.44 |
$8.20 |
2.74 |
2022-06-30 |
38.88 |
$9.33 |
4.17 |
2022-03-31 |
71.28 |
$8.62 |
8.26 |
2021-12-31 |
79.20 |
$7.20 |
10.99 |
2021-09-30 |
187.20 |
$5.59 |
33.49 |
2021-06-30 |
197.28 |
$1.47 |
134.15 |
2021-03-31 |
263.52 |
$0.42 |
630.23 |
2020-12-31 |
371.52 |
0 |
0.00 |
2020-09-30 |
675.36 |
0 |
0.00 |
2020-06-30 |
509.76 |
0 |
0.00 |
2020-03-31 |
167.04 |
0 |
0.00 |
2019-12-31 |
233.28 |
0 |
0.00 |
2019-09-30 |
123.84 |
0 |
0.00 |
2019-06-30 |
90.00 |
0 |
0.00 |
2019-03-31 |
216.00 |
0 |
0.00 |
2018-12-31 |
357.12 |
0 |
0.00 |
2018-06-30 |
360.00 |
0 |
0.00 |
2018-03-31 |
299.52 |
0 |
0.00 |
2017-12-31 |
325.44 |
0 |
0.00 |
2017-09-30 |
480.96 |
0 |
0.00 |
2017-06-30 |
368.44 |
0 |
0.00 |
2017-03-31 |
446.40 |
0 |
0.00 |
2016-12-31 |
290.88 |
0 |
0.00 |
2016-09-30 |
325.44 |
0 |
0.00 |
2016-06-30 |
986.40 |
0 |
0.00 |
2016-03-31 |
732.96 |
0 |
0.00 |
2015-12-31 |
475.20 |
0 |
0.00 |
2015-09-30 |
419.04 |
0 |
0.00 |
2015-06-30 |
753.12 |
0 |
0.00 |
2015-03-31 |
1015.20 |
0 |
0.00 |
2014-12-31 |
849.60 |
0 |
0.00 |
2014-09-30 |
791.93 |
0 |
0.00 |
2014-06-30 |
1164.96 |
0 |
0.00 |
2014-03-31 |
1206.72 |
0 |
0.00 |
Sector |
Industry |
Market Cap |
Revenue |
Medical |
Medical - Generic Drugs |
$0.007B |
$0.005B |
Evoke Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. The Company's lead product candidate, EVK-001, is in late stage clinical testing which is intended for the treatment of diabetic gastroparesis. Evoke Pharma, Inc. is based in San Diego, California.
|